A randomized phase ll study consistiong S-1+DTX and S-1+CDDP for advanced/metastatic gastric cancer without any mesurable lesions (HERBIS-3).

Trial Profile

A randomized phase ll study consistiong S-1+DTX and S-1+CDDP for advanced/metastatic gastric cancer without any mesurable lesions (HERBIS-3).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Docetaxel
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms HERBIS-3
  • Most Recent Events

    • 18 Aug 2012 Actual initiation date changed from 1 Aug 2011 to 22 Aug 2011 added as reported by University Hospital Medical Information Network - Japan
    • 22 Nov 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 22 Nov 2011 Actual initiation date Aug 2011 added as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top